SAN DIEGO -
Amira Pharmaceuticals, Inc. announced today the submission of an Investigational New Drug application (IND) of AM461, its internally-discovered, oral drug candidate for the treatment and control of inflammatory and allergic disease linked to the arachidonic acid pathway, to the U.S. Food and Drug Administration.
AM461 is an oral, selective antagonist of the receptor DP2, which recent studies have shown to be a potential target for the treatment of asthma, chronic obstructive pulmonary disease (COPD) and allergic rhinitis. The submission of the AM461 IND follows closely on the heels of Amira’s lead DP2 antagonist, AM211, which is currently in Phase I human testing.
“Taking two DP2 candidates into clinical trials within four months of each other demonstrates our conviction to the target as well as the depth of our DP2 program,” said Peppi Prasit, Chief Scientific Officer. “AM461 is structurally and metabolically distinct from AM211.”
DP2 is also known as CRTH2, or chemoattractant receptor-homologous molecule expressed on Th2 lymphocytes. DP2 is a high affinity receptor for the prostaglandin D2 and, in humans, is implicated in Th2-dependent allergic inflammation.
About Amira
Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory disease. Our discovery team is building on unparalleled insights into bioactive lipid pathways and complex signaling processes controlling many conditions including asthma, chronic obstructive pulmonary disease, cardiovascular and fibrotic diseases. Amira has a partnership with GlaxoSmithKline for the development of FLAP (5-lipoxygenase activating protein) inhibitors in respiratory and cardiovascular disease.
Amira combines the rigor of a big pharmaceutical company with the ingenuity and energy of a small company, creating an environment for efficient development of novel compounds and effective pre-clinical and clinical program decisions. Its scientific founders have successfully worked together for more than a decade and were pivotal in the discovery of a number of inflammatory drugs, including Singulair(R). The drug hunters at Amira are now actively leveraging their history of success to create high-value compounds for the future. For more information, visit www.amirapharm.com.
Source: Amira Pharmaceuticals, Inc.
Ian Stone of Russo Partners, +1-619-528-2220, ian.stone at russopartnersllc.com, for Amira Pharmaceuticals, Inc.
Related Press Releases
Epix Pharmaceuticals, Inc. Announces a Successful Auction Sale of Five Drug Program Intellectual Properties on September 30, 2009September 30th, 2009 WELLESLEY HILLS, Massachusetts -
Joseph F. Finn, Jr., C.P.A.
Takeda to Establish Four Sales and Marketing Subsidiaries to Expand its Operations in Mexico, Turkey and Five Other Countries in EuropeSeptember 30th, 2009 OSAKA, Japan - Takeda Pharmaceutical Company Limited (Osaka, Japan, "Takeda") announced today it will establish four new commercial subsidiaries covering Mexico, Turkey, Sweden, Norway, Denmark, Belgium and Luxembourg. The new subsidiaries - Takeda Pharmaceuticals Mexico, S.A.
Epix Pharmaceuticals, Inc. Announces the PRX-08066 Therapeutics Program in Phase 2 for Respiratory Indication Will Be Part of The Intellectual Property Offered for Sale at the September 30, 2009 AuctionAugust 17th, 2009 WELLESLEY HILLS, Massachusetts -
Joseph F. Finn, Jr., C.P.A.
Epix Pharmaceuticals, Inc. Announces PRX-07034 Therapeutics - CNS Phase 2 Will be Part of the Intellectual Property Offered for Sale at the September 30, 2009 AuctionAugust 10th, 2009 WELLESLEY HILLS, Massachusetts -
Joseph F. Finn, Jr., C.P.A.
Supportive Care in Cancer: Palonosetron Recommended 5-HT3 Antagonist for Emesis Prevention by MASCC/ESMOJune 29th, 2009 LUGANO, Switzerland -
- Anticipated at the Rome 2009 MASCC International Symposium the Outcome of the 2009 Joint MASCC (Multinational Association for Supportive Care in Cancer)/ESMO (European Society of Medical Oncology) Antiemetic Guideline Update Meeting New important acknowledgment for palonosetron, the second generation 5-HT3 receptor antagonist for prevention of chemotherapy induced nausea and vomiting (CINV). In April, the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology on Antiemesis included palonosetron, as the "preferred" 5-HT3 antagonist in the combined regimen recommended for emesis prevention in patients undergoing highly emetogenic chemotherapy (HEC).
Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data for AM211, a Novel Product Candidate for the Treatment of Respiratory DiseasesJune 29th, 2009 SAN DIEGO -
- Results Demonstrate Positive Proof of Mechanism
Amira Pharmaceuticals, Inc. announced today initial positive data from a Phase 1 clinical study of AM211, the company's oral selective antagonist of the DP2 (also known as CRTH2) receptor.
Amira Pharmaceuticals to Present Preclinical Data from LPA1 Receptor Antagonist Program at FASEB Summer Research ConferenceJune 14th, 2009 SAN DIEGO - Amira Pharmaceuticals, Inc. announced today that it will present preclinical data from its LPA1 receptor antagonist program on June 30, 2009 at the Federation of American Societies for Experimental Biology (FASEB) Summer Research Conference in Carefree, Arizona.
Amira Initiates Phase I Clinical Trial of Novel DP2 AntagonistApril 19th, 2009 SAN DIEGO - Trial Will Evaluate Safety, Proof of Mechanism of a Potential Oral Antagonist for the Treatment of Asthma and COPD
Amira Pharmaceuticals, Inc., announced today the initiation of a Phase I clinical study of AM211, its internally discovered oral drug candidate for the treatment and control of inflammatory and allergic diseases linked to the arachidonic acid pathway. AM211 is an oral, selective antagonist of the receptor DP2, which recent studies have shown to be a potential target for the treatment of asthma, chronic obstructive pulmonary disease (COPD) and allergic rhinitis.
Palonosetron "Preferred" 5-HT3 Antagonist for Emesis Prevention in Oncology Patients Receiving Highly Emetogenic ChemotherapyApril 1st, 2009 LUGANO, Switzerland - A new release of the NCCN (National Comprehensive Cancer Network) Clinical Practice Guidelines in Oncology on Antiemesis recommends palonosetron as the "preferred" 5-HT3 antagonist in combination with aprepitant and dexamethasone for prevention of emesis in highly emetic risk chemotherapy. Based on the important multicenter study published in The Lancet Oncology by the equipe of Dr.
Another LNA-based RNA Inhibitor Enters Clinical TrialsMarch 19th, 2009 COPENHAGEN - EZN3042 - a Survivin Inhibitor Jointly Developed by Enzon
Pharmaceuticals and Santaris Pharma Advances into the Clinic for Patients
With Solid Tumors and Lymphomas
Santaris Pharma announced today that the fourth LNA-based drug
has been brought into the clinic. In the USA several patients with cancer
have now been treated with the Company's Survivin inhibitor, which is jointly
developed by Santaris Pharma and Enzon Pharmaceuticals.
Related News
Watson Pharmaceuticals' CFO takes leave of absence, health reasons citedJuly 27th, 2009 Watson Pharmaceuticals' CFO takes leaveMORRISTOWN, N.J. — Watson Pharmaceuticals Inc.
RXi Pharmaceuticals CFO DiPalma leaving Aug. 28; company plans to recruit a replacementAugust 21st, 2009 RXi Pharmaceuticals CFO leaving Aug. 28WORCESTER, Mass.
Cyclacel Pharmaceuticals receives warning letter, faces Nasdaq delistingAugust 28th, 2009 Cyclacel Pharmaceuticals faces Nasdaq delistingBERKELEY HEIGHTS, N.J. — Cyclacel Pharmaceuticals Inc.
Valeant Pharmaceuticals International acquires Private Formula International HoldingsSeptember 30th, 2009 Valeant Pharmaceuticals buys Private Formula Int.ALISO VIEJO, Calif. — Valeant Pharmaceuticals International said Wednesday it will buy Private Formula International Holdings Pty Ltd., a skin care company, to boost its dermatology portfolio.
GlaxoSmithKline Pharmaceuticals net sales up 9.3 percentApril 28th, 2009 MUMBAI - GlaxoSmithKline Pharmaceuticals Limited has announced its financial results for the first quarter ended March 31. The Company has posted a net sales growth of 9.3 per cent compared to the previous quarter, while Profit Before Tax has grown by 7.9 percent, on a comparable basis.
Wisconsin submits proposal to reopen Janesville plant making GM's new smaller carsJune 17th, 2009 Wisconsin submits proposal to revive GM plantJANESVILLE, Wis. — Wisconsin has submitted a proposal to General Motors Corp.
King Pharmaceuticals says 2nd quarter profit falls, but performance tops expectationsAugust 6th, 2009 King Pharmaceuticals reports 2Q profit dropBRISTOL, Tenn. — Drug developer King Pharmaceuticals said Thursday its second-quarter profit dropped, as generic competition continued to hurt drug sales.
Watson Pharmaceuticals offering $850 million in mix of senior notesAugust 18th, 2009 Watson offering $850 million in notesMORRISTOWN, N.J. — Drug developer Watson Pharmaceuticals Inc.
Korean, US ships rescue Egyptian ship attacked by piratesMay 15th, 2009 SANA'A - A South Korean warship and a US destroyer rescued an Egyptian ship and captured the 17 Somali pirates who attacked it off the coast of Yemen, the US Navy said Thursday. The Korean destroyer ROKS Munmu the Great and US guided-missile cruiser USS Gettysburg responded to a distress call from the Egyptian-flagged MV Amira Wednesday after it was attacked by pirates, the US Navy's Bahrain-based 5th Fleet said in a statement.
Omar Abdullah submits resignationJuly 28th, 2009 SRINAGAR - Jammu and Kashmir Chief Minister Omar Abdullah resigned Tuesday after being linked to a sex scandal by the opposition. He submitted his resignation to Governor N.N.
